| Source publication date | (update date shown as 2026-09-17) |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Testosterone and hormone clinic or telehealth website |
| Population | Men |
| Source | Acibadem International |
| URL | acibademinternational.com/blog/enclomiphene-the-trt-alternative-explained-how-it-works-the-evidence-and-its-regulatory-status (opens in a new tab) |
Specific Claim Evaluated
Enclomiphene has never been approved by the FDA, EMA or MHRA; in short randomized trials sperm concentration was essentially unchanged, but no trial measured pregnancy or live birth and the trials did not show a convincing symptom benefit over placebo.
Primary Research Supporting or Contradicting the Claim
In 2 parallel phase 3 trials in overweight men with secondary hypogonadism, enclomiphene raised total testosterone and maintained sperm concentration in the normal range over 16 weeks, while testosterone gel reduced sperm concentration; pregnancy was not an end point (Kim et al., 2016).
Corrected Evidence-Based Interpretation
The article is correct. Enclomiphene raises testosterone and preserves sperm concentration over months, but its effect on fertility outcomes and long-term safety is unknown.
Rationale for Grade
The article separates hormonal and semen end points from clinical outcomes, states the regulatory status accurately and identifies the absence of long-term data. Its date fields are inconsistent, but the content is consistent with the primary trials.
References
- Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU Int. 2016;117(4):677-685. PMID
Supporting excerpt: "Enclomiphene citrate treatment maintained sperm concentrations in the normal range."